论文部分内容阅读
用双抗体夹心酶联免疫吸附试验检测５４例慢性粒细胞白血病（ＣＭＬ）患者血清可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）水平。结果显示：各期ＣＭＬ患者血清ｓＩＬ－２Ｒ水平均显著高于正常对照，且和病情的严重程度密切相关，ＣＭＬ急变治疗后，有效者血清ｓＩＬ－２Ｒ水平显著低于化疗前；无效者血清ｓＩＬ－２Ｒ不低，甚至高于化疗前。急粒变时血清ｓＩＬ－２Ｒ水平与外周血白细胞数、原始粒细胞绝对数及骨髓原始粒细胞绝对数呈正相关。血清ｓＩＬ－２Ｒ水平可作为ＣＭＬ分期、监测ＣＭＬ急变、判定预后的一个有用的指标。
Serum soluble interleukin 2 receptor (sIL-2R) levels were measured in 54 patients with chronic myelogenous leukemia (CML) using double antibody sandwich enzyme-linked immunosorbent assay. The results showed that the levels of serum sIL-2R in CML patients at all stages were significantly higher than those in normal controls and closely related to the severity of the disease. After acute CML treatment, the levels of sIL-2R in patients with CML were significantly lower than those before chemotherapy; -2R is not low, even higher than before chemotherapy. Serum levels of sIL-2R in acute granulopathy were positively correlated with the number of leukocytes in peripheral blood, the absolute number of primitive myelocytes and the absolute number of bone marrow myeloblasts. Serum sIL-2R levels can be used as a CML staging, CML monitoring emergency, to determine the prognosis of a useful indicator.